Geen categorie
11 januari 2021
ROTTERDAM, The Netherlands, January 11, 2021 – The partnership between the young company Pan Cancer T B.V. and Erasmus MC is awarded a Health~Holland grant of […]
18 januari 2023
– Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 – […]
30 maart 2021
– John Tchelingerian, PhD (Chair), Dharminder Singh Chahal and Prof. Dr. Chris Bangma to form Supervisory Board ROTTERDAM, March 30, 2021 – Pan Cancer T B.V., […]
28 oktober 2021
Expanded investor syndicate strengthens the company’s financial position and investor base ROTTERDAM, October 28, 2021 – Pan Cancer T B.V., a biotech spin-off from the […]
15 april 2021
Pan Cancer T is awarded with Axon Innovation for Health Award 2021 – selected as the winner out of 21 start-up companies Hilversum, 15 April 2021 […]
7 februari 2021
Press Release: Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
Life-saving TCR T-cell therapies for hard-to-treat solid tumors – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and […]
1 september 2021
TCR T cells towards solid tumors: perspective on pitfalls and opportunities Reno Debets, founder and CSO, PCT BV, Rotterdam, the Netherlands Rationale Adoptive T cell […]